News Daily News El Uso Crónico de un Antagonista de la Vitamina K Aumenta las Hemorragias Intrahospitalarias en Pacientes sometidos a PCI Primarias Caitlin E. Cox November 02, 2014
News Daily News Chronic Vitamin K Antagonist Use Ups In-Hospital Bleeding Among Primary PCI Patients Caitlin E. Cox November 02, 2014
News Features Thoughtful Insights at TCT: Uncertainty Surrounds Antithrombotic Therapy in PCI Patients Who Require Anticoagulation Todd Neale October 10, 2014
News Conference News TCT 2014 Thoughtful Insights at TCT: Uncertainty Surrounds Antithrombotic Therapy in PCI Patients Who Require Anticoagulation Todd Neale October 10, 2014
Presentation TCT 2014 TCT 475: Triple Antithrombotic Therapy Versus Dual Antiplatelet Therapy in Patients with Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Dong Oh Kang September 15, 2014
Presentation TCT 2014 TCT 474: Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndromes: The AVIATOR Registry Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Georgios Christodoulidis September 15, 2014
Presentation TCT 2014 When Should Aspirin Be Dropped From Triple Therapy? Musings on Woest and Beyond Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Harvey D. White September 15, 2014
Presentation TCT 2014 Reversal of Factor Xa Inhibition Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Lisa K. Jennings September 15, 2014
Presentation TCT 2014 Edoxaban in ACS and Atrial Fibrillation: Risk/Benefit Analysis and Future Directions Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Michael D. Ezekowitz September 15, 2014
Presentation TCT 2014 Apixaban in ACS and Atrial Fibrillation: Comparison to Warfarin and Aspirin Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Christopher B. Granger September 15, 2014
Presentation TCT 2014 Rivaroxaban in ACS and Atrial Fibrillation: Randomized Trials, Real-World Data, and Pioneering Efforts Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson September 15, 2014
Presentation TCT 2014 Dabigatran in ACS and Atrial Fibrillation: MI Risks, Safety in the Elderly, and the RE-DUAL Trial Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Laura Mauri September 15, 2014
Presentation TCT 2014 Comparative Analysis of Warfarin and the NOACs: Differentiating Properties, Risks, and Benefits Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Jonathan L. Halperin September 15, 2014
Presentation TCT 2014 The REG1 Anticoagulation System: Factor IX Inhibitor Using RNA Aptamer Technology Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, A. Michael Lincoff September 15, 2014
Presentation TCT 2014 The Triple Therapy Conundrum: Treatment of the PCI Patient with Atrial Fibrillation Presenter: Matthew J. Price, C. Michael Gibson September 15, 2014
Presentation TCT 2014 ISAR-TRIPLE: A Prospective, Randomized Trial of Six Weeks Versus Six Months of Clopidogrel in Patients Treated with Concomitant Aspirin and Oral Anticoagulant Therapy Following Coronary Drug-Eluting Stent Implantation Presenter: Roxana Mehran, Harvey D. White, Nikolaus Sarafoff September 15, 2014
News Industry News New Study Evaluates “Triple Therapy” Regimens After Drug-Eluting Stenting in Patients Requiring Oral Anticoagulation September 15, 2014
Presentation TCT 2014 Does Cilostazol Have a Role as an Antiplatelet Agent in the Contemporary DES Era (and in Triple Therapy Decisions)? Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Frederick Feit September 14, 2014